文献速递关节外科创伤骨科

近期接受糖皮质激素注射的快速进展性骨关节炎患者行全髋关节置换术前的特殊考量

Special Considerations Before Total Hip Arthroplasty for Rapidly Progressive Osteoarthritis With a Recent Corticosteroid Injection.
PubMed 文献 · J Arthroplasty · 2025-03-15

该回顾性研究在单中心纳入2014年1月至2023年1月影像报告,最终81例因糖皮质激素注射后快速进展性髋骨关节炎行全髋关节置换术,平均随访2年。8例术前关节穿刺培养均阴性,2例术后1个月内发生假体周围感染,均未行术前感染筛查。作者认为糖皮质激素注射相关快速进展性骨关节炎行全髋关节置换术的假体周围感染风险估计为2.5%,可考虑术前炎性标志物筛查和关节穿刺。

要点

  • 糖皮质激素注射后快速进展性髋骨关节炎行全髋关节置换术的假体周围感染风险估计为2.5%。
  • 8例术前关节穿刺平均细胞计数1410.8(SD=1574.2)、多形核细胞百分比52.3%(SD=23.3),培养均阴性。
  • 2例术后1个月内发生假体周围感染,均未行术前炎性标志物或关节穿刺筛查。

核心结论

  • 糖皮质激素注射后快速进展性髋骨关节炎行全髋关节置换术的假体周围感染风险估计为2.5%。
  • 作者认为,对糖皮质激素注射相关快速进展性髋骨关节炎患者,全髋关节置换术前可考虑炎性标志物筛查和可能的关节穿刺。

研究设计与样本

  • 单中心回顾性研究,2014年1月至2023年1月共识别4279份快速进展性骨关节炎影像报告,去重后对2175例患者逐一查阅病历。
  • 快速进展性骨关节炎定义为髋部糖皮质激素注射后1年内软骨丢失至少2 mm/年或关节间隙丢失50%。
  • 排除既往恶性肿瘤、化脓性关节炎、口服糖皮质激素或股骨头坏死者,最终81例因糖皮质激素注射后快速进展性髋骨关节炎行全髋关节置换术,平均随访2年。

主要发现

  • 31例因炎性标志物、8例因术者判断行术前感染筛查,其中8例行髋关节穿刺。
  • 关节穿刺平均细胞计数1410.8(SD=1574.2),平均多形核细胞百分比52.3%(SD=23.3),所有穿刺培养均阴性。
  • 8例穿刺患者穿刺及术中培养均阴性,均未发生假体周围感染。
  • 2例在全髋关节置换术后1个月内发生假体周围感染,均未行术前炎性标志物或关节穿刺筛查;无其他患者再次手术。

关键数值与推荐

  • 快速进展性骨关节炎定义:糖皮质激素注射后1年内软骨丢失至少2 mm/年或关节间隙丢失50%。

临床怎么用

  • 作者认为,对糖皮质激素注射相关快速进展性髋骨关节炎患者,全髋关节置换术前可考虑炎性标志物筛查和可能的关节穿刺。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapidly progressive osteoarthritis (RPOA) has been associated with hip corticosteroid injections (CSIs), but may also mimic septic arthritis, which demonstrates similar erosive findings. This retrospective review evaluated a consecutive series of patients who had RPOA of the hip following CSI who underwent total hip arthroplasty (THA) and assessed outcomes and potential infection screening implications. METHODS: All radiographic reports concerning RPOA were retrospectively identified at a single academic referral center from January 2014 to January 2023. A total of 4,279 reports were identified, and after removing duplicates, 2,175 patients were individually chart-reviewed. The occurrence of RPOA was defined as chondrolysis of at least 2 mm per year or 50% of joint space loss within 1 year of a CSI of the hip. Patients who had prior malignancy, septic arthritis, oral corticosteroid use, or femoral head osteonecrosis were excluded. RESULTS: Ultimately, 81 patients, who had a mean follow-up time of 2 years, were identified who had undergone THA for RPOA following CSI. Preoperative infectious workup was performed in 31 patients who have inflammatory markers and eight patients who have a hip aspiration based on surgeon discretion. The mean aspiration cell counts and polymorphonuclear percentages were 1,410.8 (SD = 1,574.2) and 52.3% (SD = 23.3), respectively. Cultures were negative in all aspirations. All eight patients had negative aspirations and negative intraoperative cultures, and none developed periprosthetic joint infection (PJI). There were two patients who developed PJI within 1 month following THA, and neither underwent a preoperative infectious workup with labs or aspirations. No other patients underwent repeat surgery. CONCLUSIONS: The occurrence of RPOA of the hip following CSI was associated with an estimated 2.5% risk of PJI. Preoperative screening with inflammatory markers and possible joint aspiration should be considered prior to THA for patients who have CSI-related RPOA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Rainey JP, Taylor AJ, Radtke LE, et al. Special Considerations Before Total Hip Arthroplasty for Rapidly Progressive Osteoarthritis With a Recent Corticosteroid Injection. J Arthroplasty. 2025. PMID: 40097122. doi:10.1016/j.arth.2025.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。